TWiV 967: Clinical update with Dr. Daniel Griffin
In his weekly clinical update Dr. Griffin discusses how immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection, prevalence of SARS-CoV-2 and influenza coinfection and clinical characteristics among children and adolescents aged Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Immunological dysfunction persists for 8 months following SARS-CoV-2 infection (Nature)
- Prevalence of SARS-CoV-2 and Influenza coinfection and clinical characteristics (CDC)
- WHO estimates of excess mortality associated with the COVID-19 pandemic (Nature)
- Reconsideration of anti-nucleocapsid IgG antibody as a marker of SARS-CoV-2 infection (OFID)
- Impact of SARS-CoV-2 variants on inpatient clinical outcome (CID)
- Clinical features and burden of post-acute sequelae of SARS-CoV-2 infection (OFID)
- Similar SARS-CoV-2 Ct value distributions in samples from symptomatic children (JPIDS)
- Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19 (CDC)
- Effect of Nirmatrelvir/Ritonavir vs placebo on COVID-19─Related hospitalizations (OFID)
- COVID-19 Convalescent Plasma outpatient therapy to prevent outpatient hospitalization (MedRxiv)
- Bacterial co-infection and empirical antibiotic therapy in patients with COVID-19 (OFID)
- Association of time to surgery after COVID-19 infection (JAMA)
- Demonstration of stable clusters of symptoms in long COVID (OFID)
- Paxlovid patient eligbiliity screening checklist (FDA)
- Longitudinal analysis of T cells in COVID-19 survivors with post-acute sequelae (OFID)
- Contribute to our MicrobeTV fundraiser at PWB
- Dr. Griffin's treatment guide (pdf)
- Letters read on TWiV 967
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv
More description
In his weekly clinical update Dr. Griffin discusses how immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection, prevalence of SARS-CoV-2 and influenza coinfection and clinical characteristics among children and adolescents aged Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Immunological dysfunction persists for 8 months following SARS-CoV-2 infection (Nature)
- Prevalence of SARS-CoV-2 and Influenza coinfection and clinical characteristics (CDC)
- WHO estimates of excess mortality associated with the COVID-19 pandemic (Nature)
- Reconsideration of anti-nucleocapsid IgG antibody as a marker of SARS-CoV-2 infection (OFID)
- Impact of SARS-CoV-2 variants on inpatient clinical outcome (CID)
- Clinical features and burden of post-acute sequelae of SARS-CoV-2 infection (OFID)
- Similar SARS-CoV-2 Ct value distributions in samples from symptomatic children (JPIDS)
- Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19 (CDC)
- Effect of Nirmatrelvir/Ritonavir vs placebo on COVID-19─Related hospitalizations (OFID)
- COVID-19 Convalescent Plasma outpatient therapy to prevent outpatient hospitalization (MedRxiv)
- Bacterial co-infection and empirical antibiotic therapy in patients with COVID-19 (OFID)
- Association of time to surgery after COVID-19 infection (JAMA)
- Demonstration of stable clusters of symptoms in long COVID (OFID)
- Paxlovid patient eligbiliity screening checklist (FDA)
- Longitudinal analysis of T cells in COVID-19 survivors with post-acute sequelae (OFID)
- Contribute to our MicrobeTV fundraiser at PWB
- Dr. Griffin's treatment guide (pdf)
- Letters read on TWiV 967
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.